Stock Market Reviews

IRD (Opus Genetics, Inc.) News

Get the latest news, insights, and market updates on IRD (Opus Genetics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease
  Emerging gene therapy administered through a one-time subretinal injection marks a major milestone for the inherited retinal disease community Initial data expected in Q1 2026 RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the first par
  Nov 13, 2025 - $IRD
• Opus Genetics, Inc. (IRD) Reports Q3 Loss, Beats Revenue Estimates
  Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of +14.29% and +11.36%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 12, 2025 - $IRD
• Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update
  - Positive 3-month pediatric and 18-month adult clinical data from OPGx-LCA5 Phase 1/2 trial support the potential for restoring cone-mediated vision -- Successful FDA RMAT meeting provides the potential for an accelerated regulatory pathway to approval for OPGx-LCA5 -- OPGx-BEST1 gene therapy program underway with recruitment ongoing in Phase 1/2 trial for the treatment of BEST1 disease -- Supplemental New Drug Application submission planned by year-end 2025 for Phentolamine Ophthalmic Solution
  Nov 12, 2025 - $IRD
• Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates
  Zymeworks (ZYME) delivered earnings and revenue surprises of +13.33% and -2.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 6, 2025 - $IRD
• Opus Genetics Announces $23 Million Registered Direct Offering
  - Financing led by Perceptive Advisors and Balyasny Asset Management - - Proceeds targeted to fund rapid development of ophthalmic gene therapy clinical programs - RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”) a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced th
  Nov 6, 2025 - $IRD
• Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease
  Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides the potential for an accelerated regulatory pathway to approval of OPGx-LCA5First participant enrolled in run-in period for planned adaptive Phase 3 trialCompany intends to apply for the FDA’s new Rare Disease Evidence Principles (RDEP) review processOPGx-LCA5 has the potential to be the first gene therapy and one-time treatment for Leber congenital amaurosis (LCA) type 5Recent $23 million financing led by Perceptive Advis
  Nov 6, 2025 - $IRD
• Fortrea Holdings Inc. (FTRE) Q3 Earnings Lag Estimates
  Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of -25.00% and +9.21%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 5, 2025 - $IRD
• Analysts Estimate Alvotech (ALVO) to Report a Decline in Earnings: What to Look Out for
  Alvotech (ALVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Nov 5, 2025 - $IRD
• Opus Genetics, Inc. (IRD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
  Opus Genetics, Inc. (IRD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Nov 4, 2025 - $IRD
• Amgen (AMGN) Q3 Earnings and Revenues Beat Estimates
  Amgen (AMGN) delivered earnings and revenue surprises of +12.80% and +6.87%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 4, 2025 - $IRD